Mobia Medical Reimbursement Overview
for the Vivistim® Program
June 24, 2026
Original Air Date
On-Demand Webinar
Guest Speaker:
Denal Wilson
Director Brain Services
AdventHealth
Bridget Kluesner
Director Brain Services
AdventHealth
Navigating reimbursement is critical to the success of any Vivistim® Program. Join the Mobia Medical Market Access team and a Director of Brain Services at AdventHealth for a webinar covering market access conditions and real-world implementation and financial performance of a Vivistim program.
Topics Discussed
- 2026 Medicare reimbursement updates
- Coding and billing best practices
- The importance of proactive claim reviews
- Strategies to help optimize reimbursement
- Partnership opportunities to support successful Vivistim Program implementation
- Q&A
Watch
On-Demand Now!
Please complete this form for access to the webinar.
The Vivistim® Paired VNS™ System (Vivistim) is intended to be used to stimulate the vagus nerve during rehabilitation therapy in order to reduce upper extremity motor deficits and improve motor function in chronic ischemic stroke patients with moderate to severe arm impairment. Do not use if you have had a bilateral or left cervical vagotomy. Risks may include, but are not limited to pain after surgery, hoarseness, bruising, swelling, coughing and throat irritation. Infection leading to explant is a risk associated with any device surgery. For full safety information, please see www.vivistim.com/safety. Individual results may vary.
© 2026 Mobia Medical, Inc. All rights reserved. Vivistim, Vivistim Therapy, Paired VNS, Serenity, and the Mobia Medical logo are trademarks of Mobia Medical, Inc